Novelion Therapeutics Inc (NASDAQ:NVLN) (TSE:QLT) has received a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.
Zacks has also assigned Novelion Therapeutics an industry rank of 64 out of 255 based on the ratings given to its competitors.
NVLN has been the subject of a number of research analyst reports. ValuEngine upgraded shares of Novelion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research cut shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, February 12th.
NASDAQ:NVLN traded up $0.01 during trading hours on Thursday, reaching $1.33. 10,172 shares of the company were exchanged, compared to its average volume of 140,130. The stock has a market capitalization of $25.30 million, a PE ratio of -0.23 and a beta of 2.18. Novelion Therapeutics has a twelve month low of $0.70 and a twelve month high of $4.79.
Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) last posted its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.13). The business had revenue of $40.71 million for the quarter, compared to the consensus estimate of $40.90 million. Equities research analysts predict that Novelion Therapeutics will post -2.94 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in shares of Novelion Therapeutics in the fourth quarter valued at about $25,000. Geode Capital Management LLC raised its position in shares of Novelion Therapeutics by 45.7% in the fourth quarter. Geode Capital Management LLC now owns 82,901 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 26,003 shares during the last quarter. Finally, Highbridge Capital Management LLC acquired a new stake in shares of Novelion Therapeutics in the fourth quarter valued at about $795,000. Institutional investors and hedge funds own 42.68% of the company’s stock.
About Novelion Therapeutics
Novelion Therapeutics Inc, a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand.
Featured Article: Commodities
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.